Table 1.

Distribution of CTL Responses (breadth and strength) between HIV proteins

Protein	No. of Peptides		No. of OLP targeted at least once in the cohort (%)		No. of subjects with responses (%)		CTL strength (Mean ± SD) (SFC/106 PBMC)
	B	C	B	C	B	C	B	C
Gag-p17*	17	17	14(82.4%)	16(94.1%)	32(53.3%)	43(71.7%)	610 ± 1185	964 ± 1340
Gag-p24	31	31	30(96.8%)	30(96.8%)	51(85.0%)	52(86.7%)	3155 ± 3894	2935 ± 3390
Gag-p15	19	19	12(63.2%)	13(68.4%)	32(53.3%)	34(56.7%)	767 ± 1495	698 ± 1290
Gag	67	67	56(83.6%)	59(88.1%)	55(91.7%)	54(90.0%)	4532 ± 5512	4597 ± 5073
Pol – Pro*#	21	21	12(57.1%)	6(28.6%)	22(36.7%)	11(18.3%)	437 ± 949	240 ± 729
Pol – RT*	59	59	40(67.8%)	47(79.7%)	46(76.7%)	53(88.3%)	1047 ± 1461	2104 ± 2691
Pol – Rnase*	17	17	9(52.9%)	12(70.6%)	14(23.3%)	33(55.0%)	250 ± 1066	562 ± 1258
Pol – Int	36	36	27(75.0%)	30(83.3%)	38(63.3%)	42(70.0%)	864 ± 1158	922 ± 1228
Pol*	133	133	88(66.2%)	95(71.4%)	52(86.7%)	58(96.7%)	2598 ± 3069	3828 ± 4090
Env-gp120*	68	68	28(41.2%)	39(57.4%)	32(53.3%)	38(63.3%)	690 ± 1445	1034 ± 2062
Env-gp41*	46	46	17(37.0%)	31(67.4%)	29(48.3%)	45(75.0%)	649 ± 1377	943 ± 1389
Env*	114	114	45(39.5%)	70(61.4%)	46(76.7%)	52(86.7%)	1339 ± 2040	1976 ± 2624
Nef	27	27	26(96.3%)	24(88.9%)	52(86.7%)	51(85.0%)	2727 ± 4305	2812 ± 4217
Rev	15	14	10(66.7%)	9(64.3%)	18(30.0%)	28(46.7%)	552 ± 1421	590 ± 1105
Tat	13	13	7(53.8%)	6(46.2%)	10(16.7%)	9(15.0%)	283 ± 1103	132 ± 496
Vpu*#	9	9	8(88.9%)	3(33.3%)	9(15.0%)	3(5.0%)	144 ± 535	24 ± 115
Vpr	11	11	10(90.9%)	11(100%)	27(45.0%)	27(45.0%)	532 ± 1070	522 ± 988
Vif	24	24	13(54.2%)	19(79.2%)	20(33.3%)	37(61.7%)	576 ± 1627	762 ± 1483
Total *	413	412	263(63.7%)	296(71.8%)	60(100%)	60(100%)	13283 ± 14223	15242 ± 14353

1. * denotes a significant difference in responses targeting clade B and C OLPs (p value < 0.05, paired t test).

2. # denotes that the CTL responses to clade B OLPs targeting protease and Vpu are significantly stronger and broader than to clade C OLPs